on you quarter thank our third conference Trip. Thanks, XXXX morning, Good and for call. joining everyone, us
a over reporting increase our year-over-year another XXXX, extremely high we always, we the record in and quarter third helped kids proud are As of for call XX,XXX OrthoPediatrics. XX% open by to that
while expanding and This far lives and and continue children impacting positively deliver our XXX,XXX be costs the over so children measure always inception, our we reach over of best this has our to worldwide. since on will million and of foundation our and success. our helped the year more Having X remains more
the topline Investor dedicating revenue into in breakeven the future. and plan flow than deliver each and and At and teens while for margin, to cash now EBITDA We to held deliver high EBITDA September, and business clearly our deeper business, articulated how produce our recent Day support we OPSB, early become our to X-year look time XX% substantial we a segment greater improving provided in our plan in value cause XXXX. in growth
Our strong to performance profile. and we our QX continue step as execute successful represents another OrthoPediatrics' unique and plan enhance in further differentiated forward yet
end, we $XX.X record OrthoPediatrics' representing XX% growth strong of of the of from third that global performance revenue in To delivered XXXX as the period continued quarter same million, in XXXX.
our and OPSB. continue both we and been entire share history, performances with in to take has long As businesses T&D both saw the strong scoliosis bolstered by from growth across business
as environment viruses Hurricane with affected or believe the of experienced future. the Milton. And transient the finally September, from we hurricane into normal we companies, the in early seasonal only at in in environment, an of overall October were we impact we other again, the as normalized Like surgical continue Looking at to cancellations. end case COVID, are resulting by and possible we expect such macro impacts a flu, RSV
have marginal favorable. healthy volumes impact have given been October QX remained However, -- on trends the and quarter, our the throughout was
guidance overall raise positive said, this bullish coupled remain levers first to to multiple That to that year compel momentum. ahead we with successfully the continue have quarters, as and more us results, of XXXX results. our us the executed outlook X growth through strategy reflect we our Strong our deliver full
We raised to XX% year million, XX%. representing range growth of XXXX revenue million to for expectation $XXX our $XXX year-over-year full of
growth, improve reduce as to and the extend We adjusted cash expect EBITDA final our of months usage we XXXX. enter
In total $XX.X third as million, the trauma addition by Boston prior quarter T&D share XXXX, revenue Now revenue of moving O&P be products to of to the of well generated across year The deformity we results of and to representing as compared market continue XX% gains period. business revenue. significant within our several our segment. the growth driven
OPSB and cannulated This quarter's and performance screws, DFX, O&P both highlighted Tibia, by sales. was Boston products, PNP trauma including
T&D drive product most set entire share from deployments, growth, the gain those increase. continue addition in we prior the continued utilization across business, to and sets Within of to our portfolio products, the will to notably the believe aforementioned continue
this of the far, driver quarter, for meet solid will a quarters working we deploy adopting launch and the Tibia which Thus rate, are and Tibia, ensure beyond. anticipate more exceptionally executed PNP growth that PNP to a remarkable we've sets at and we to hard rapidly demand. well next be are launched surgeons During several rising the sets we
of the remains been Overall, Surrounding to pipeline the ours. we need we in and and that impact provide care ensuring optimal XX focus to years, launched pediatric We technology have quality different and our further future. major bring needs. a the and are on systems they we seeing high last contributions Currently, surgeons trauma over are deformity robust. expect focus key address products unmet deployments orthopedic is have XXXX and market from the XXXX of that several the set with all
representations especially and provide our products unique for PNP Tibia are DFX of impact life-changing that great a patients.
timeline, an new postsurgical to we clinical growth continue we've full throughout quarters, several ramp believe UL Tibia ] see of success these its demand [ the rapid launch in we proud now received the release We seen for is we for in are which expand validation further continues years additional few DFX PNP is products. the recently of been exceed And a surgeon to very as market market and of U.S. will and poised to the terms expectations. access. for earlier indication demand. approval continue for treatment our paradigms outcomes has although to FDA what DFX in bracing, and the continue
product R&D On excited the development according or the the deformities of is series, we're our progressing plan particular, and surgical half year. the and launch T&D it our first adolescent there's system plating first PX for system hip side no PX, on slated of In is in with business. for This pediatric today. front, to the platform, hip of about progress pediatric fractures next other our like the and specifically of our
will world-class system opportunity to franchise. a a a with with an spawn the represents grow believe significant major within opportunities opportunity new plating and a it such, share-taking As to for this the need fill us further in indication. unmet We be market
continues across needs that be to performer to to Overall, scale, growth fill for a as and leverage us drive our market we capture market unmet T&D the strong new products bring share board.
Investor or in within growth profitability. OPSB, strategy positively have detail at the we September, that discussed clearly As will Day created specialty defined drive bracing our in business, a OrthoPediatrics nonsurgical and impact
next number per clinics; expansion. OPSB X a launching with our by strategy and products Our and share phase take products growing number the approach: one, X to existing to aggressive expand OPSB the territory over in existing the market threefold new footprint accelerating utilizes year; years two, number coming R&D to three,
A metro our growth currently, investment. as the layer average. within serve of have work, existing as easiest XX% across represents see sales the OPSB-specific to X XX% with we XX% we greater from defined we Across orthopedic estimate is a that We've target And to the we expanded clinics about those Increasing their already U.S. share on target share. markets area. of begun the from force. target currently returns XX% market we pediatric market push to first, have to work Regarding early hard markets, market share market
take On these very the additional we be this while and organic and our several partnerships. development from launching do through both own it's strategic products early year, will time, R&D front, product projects
won't already expansion, in and Day, that aggressive in With be in allows have Investor clinic a quarter, to made of since front. new impact this that have small important in growth progress are Early to territory. a happy expansion report for will Florida fourth the the these they acquisition we material greenfield we this products closed on territory in the we QX, drivers XXXX. respect While
in Additionally, completed quarter. we will are working on expect the multiple greenfield be fourth opportunities that expansion we
XXXX updates of our to years. While for all of believe with driver components are of we drive the on critical, especially the for to growth, impact capital-efficient with execute to are our patient with and providing traction territory XXXX, we track OPSB patients potential growth strategy look treating the plans more next be the look our this potential huge the in near We recognize this to strategy expansion forward through suggests remainder that early largest we and we as on several within future. will and
as the share the international scoliosis along In as of of of and scoliosis to of million, accounts revenue with the this users, several opening large we XXXX, XX% third O&P driven to by generated Moving strong new gain, business. of well global the strong quarter case growth revenue. of scheduling, new was key compared growth and growth year. continued onboarding global some addition $XX.X rebound Boston representing the scoliosis The prior quarter the
and key strong placements. RESPONSE U.S. was the robust which Spine our into has from of and accounts due are synergies Scoliosis despite we the abroad, first and surgeon quarter. business product, the weather Rib the specifically, the extended from to large OPSB O&P, of More the we adoption international the RESPONSE balance our Boston saw and scoliosis Further, continued growth in for sales strong case Southeast. to at XD revenue, cancellations products strong system scheduling Pelvic, summer with and the benefiting adoption in EOS and bracing fall contributed of
direct seeing users strong and from we're our was distributors. stocking board our strong markets, revenue to in scoliosis on where LatAm come ordering due International solid new
the XD impact and have XD institutions we account Those at units. third unit in placements we scoliosis to sales Looking where sold where In over locations of revenue next grow products. a to years. placements revenue positively units driving placed XXXX. have in are quarter, will in large X opportunity that were few and X units critical a both we had XD substantial core the multiple conversions placed in
a carry lead gross overall average, margin does which XD lower will future is selling in margin placements the while units our reflected corporate However, results. the than revenue, to
turning to our focus products. Now EOS
that all meet an the to we pathway, may data have engaged already the ensure requirements feedback approval. XXX(k) be to EOS FDA and direct received developing to approvals the continue We approval for and product the FDA with work regarding pathway toward eLLi new we in portfolio our FDA launches. been with we We've as not we collection likely secure progress VerteGlide. and approval pathway Recently, a needed discussions with
we for not the delay While a surgeons impacts do are slight opportunity, eLLi XXXX. multiple we when anticipate at impact there that locations will and revenue we which in this the do in and we being Promisingly, timing onboarded believe the our international OUS, expect look of VerteGlide positively launches. procedures first of U.S.
we'll will upcoming We approval be process. in cases leverageable data anticipate clinical our OUS, be and that capturing
distributors. Moving to primarily of growth was Growth to OUS greater OPSB and were and set that the year distributors OPSB $XX.X generating international. somewhat international Pega year-over-year. the XXX% million revenue strong, a due delivering Overall, and addition performance of trauma prior comp difficult growth, and than year international driven heavy of while QX conversion was deformity stocking international by nearly muted scoliosis in XX% complete resulted in by prior growth
demand the bolstered entire of well very growth in overall several we the quarter scoliosis expect strong from T&D to scoliosis. implant will strong, is legacy International portfolio as to devices products, primarily and as by contribute across and general, growth the revenue continue trauma deformity In and business. was the international it including
number hard and well the remains MDR are for working growth large the beyond, look to products available approval pediatric approvals. we in orthopedic United of we outside continue we States. catalyst XXXX and EU a surgeons As ahead, of to positioned our increase for
expect we the awaiting our finalize mid-XXXX. which MDR are body in We be EU completed to to notified status,
in thereafter. shortly This several will launch enable new potential Europe products the of
exploring believe the first for for will surgeries opportunities remainder VerteGlide XXXX. are nicely, and we XXXX. outside States business expect Additionally, year of further contribute OPSB, in and set Overall, improved up and expansion we eLLi the we to the of an United the from is toward the international come
hosted Society, we That experiences brings In education. in training professionals, XX during quarter, to surgeon us place third and Barcelona for including X,XXX healthcare training which the September. took unique the in Scoliosis SRS, over Research
scoliosis. portfolio expanding kids Our our highlighted products with team was carrying for and well of represented
we option, included educational publications. we ApiFix, was opportunities. continue efforts we in booth, X pediatric continue enhance recently that a our opportunities to is It lead to hosted multiple which to nonfusion treatment addition surgeon the these In our important peer-reviewed on orthopedic and training study sessions within for to industry community, provide
like With turn to that, our to provide over to results.
Fred? the more financial on Fred I'd call detail
